← Leaderboards
David McCormick
Iit Research Institute
$23,114,492
Attributed
$23,114,492
Total exposure
9
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $9.4M · FY2009–24$10M$7.5M$5M$2.5M$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$23,114,492 · 9
By mechanism
N01$22,875,921 · 9
N02$238,571 · 1
Top collaborators
No co-investigators on record.
Most similar at Iit Research Institute
Same institution · by research overlap
- Ph.d., D.a.b.t., David McCormick$2,861,154
- Ph.d. Dabt, David McCormick$2,029,696
Others in their field
Top investigators on “Toxic Effect”
- George R Seage · Abt Associates, Inc.$224,114,540
- Peter C Adamson · National Childhood Cancer Foundation$126,756,857
- Gregory H Reaman · National Childhood Cancer Foundation$123,836,183
- Carol Nesel · Westat$116,355,411
- Mary M Horowitz · Medical College Of Wisconsin$90,165,506
- Barney Sparrow · Battelle Memorial Institute$88,494,220
Research focus
Toxic EffectMalignant NeoplasmsToxicologyContractsCanis FamiliarisIn VitroDosePre-ClinicalClinical TrialsRattusPharmaceutical PreparationsSafetyOralDrug KineticsChemopreventive AgentEvaluationBaseRodentCellsTumorIn VivoAreaAnimal ModelNonhuman Primate
Grant awards (31)
PREVENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMARKERS; TASK ORDER TITLE: PRECLINICAL DEVELOPMENT OF AN RNA VACCINE FOR IMMUNOPREV$1,020,618
N01 · FY2024 · CA · contact PI
TOXICOLOGY STUDIES IN RATS AND DOGS ADMINISTERED AIT-102$568,068
N01 · FY2024 · CA · contact PI
PRECLINICAL TOXICOLOGY OF LARGE MOLECULE DRUGS DEVELOPED FOR CANCER AND OTHER INDICATIONS$300,728
N01 · FY2024 · CA · contact PI
PRECLINICAL TOXICOLOGY OF LARGE MOLECULE DRUGS DEVELOPED FOR CANCER AND OTHER INDICATIONS$1,456,819
N01 · FY2023 · CA · contact PI
Base Title: PREVENT Preclinical Pharmacology and ToxicologyTask Order Title: Nicotine Reduction Therapy Using the Human Monoclonal Antibody ATI-1013$659,489
N01 · FY2023 · CA · contact PI
TASK ORDER: TOPICAL RESATORVID FOR NONMELANOMA SKIN CANCER PREVENTIONPERIOD OF PERFORMANCE: 09/21/2020 - 03/31/2023$644,637
N01 · FY2023 · CA · contact PI
LFA-9 (mPGES-1/5-LOX Inhibitor): Preclinical Studies to Support a Clinical Trial,$418,720
N01 · FY2023 · CA · contact PI
PRECLINICAL TOXICOLOGY OF LARGE MOLECULE DRUGS DEVELOPED FOR CANCER AND OTHER INDICATIONS$750,000
N01 · FY2022 · CA · contact PI
PREVENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMARKERS; TASK ORDER TITLE: PRECLINICAL DEVELOPMENT OF AN RNA VACCINE FOR IMMUNOPREV$291,405
N01 · FY2022 · CA · contact PI
TASK ORDER: TOPICAL RESATORVID FOR NONMELANOMA SKIN CANCER PREVENTIONPERIOD OF PERFORMANCE: 09/21/2020 - 03/31/2023$156,564
N01 · FY2022 · CA · contact PI
CONTRACT ORIENTATION & KICKOFF MEETING FOR R&D SERVICES UNDER "PRECLINICAL TOXICOLOGY OF SMALL MOLECULE DRUGS DEVELOPED FOR CANCER AND OTHER INDICATIO$3,000
N01 · FY2022 · CA · contact PI
LFA-9 (mPGES-1/5-LOX Inhibitor): Preclinical Studies to Support a Clinical Trial,$844,172
N01 · FY2021 · CA · contact PI
EVALUATION OF AFPEP FOR THE PREVENTION OF BREAST CANCER$535,343
N01 · FY2021 · CA · contact PI
IGF::OT::IGF NExT Preclinical Toxicology & Pharmacology of Drugs Developed for Cancer Patients, TO#3, Exploratory Studies of CCR4 CART Cells$238,571
N02 · FY2021 · CA · contact PI
COVID-19 RELATED STUDY INVOLVING DOGS$597,893
N01 · FY2020 · CA · contact PI
SUPPORT FOR THE PRECLINICAL DEVELOPMENT OF EIF4A INHIBITORS ROCAGLAMIDE AND DIDESMETHYLROCAGLAMIDE. (TOXICIOLOGY SERVICES TO SUPPORT PRECLINICAL DRUG$588,615
N01 · FY2020 · CA · contact PI
PREVENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMARKERS; TASK ORDER TITLE: PRECLINICAL DEVELOPMENT OF AN RNA VACCINE FOR IMMUNOPREV$430,361
N01 · FY2020 · CA · contact PI
TASK ORDER: TOPICAL RESATORVID FOR NONMELANOMA SKIN CANCER PREVENTIONPERIOD OF PERFORMANCE: 09/21/2020 - 03/20/2022$213,180
N01 · FY2020 · CA · contact PI
"CONTRACT ORIENTATION AND KICKOFF MEETING", TASK ORDER #1 UNDER 75N91019D00012. TASK ORDER PERIOD OF PERFORMANCE: 1/25/2019-2/24/2019.$3,500
N01 · FY2019 · CA · contact PI
BASE IDIQ CONTRACT FOR "PREVENT PRECLINICAL DRUG DEVELOPMENT PROGRAM: TOXICOLOGY AND PHARMACOLOGY TESTING"; POP: 1/25/2019-1/24/2024.$3,500
N01 · FY2019 · CA · contact PI
Preclinical Efficacy Evaluation of the Lipid-Based SMEDDS Formulation of DIM, BR-9001,$973,931
N01 · FY2018 · CA · contact PI
LFA-9 (mPGES-1/5-LOX Inhibitor): Preclinical Studies to Support a Clinical Trial, POP 9/17/18-9/16/2020$685,688
N01 · FY2018 · CA · contact PI
IGF::OT::IGF NExT Preclinical Toxicology & Pharmacology of Drugs Developed for Cancer Patients, TO#3, Exploratory Studies of CCR4 CART Cells$479,694
N01 · FY2017 · CA · contact PI
IGF::OT::IGF NOVEL ANDROGEN RECEPTOR ANTAGONIST-MEDIATED CHEMOPREVENTION OF PROSTATE CANCER$598,583
N01 · FY2015 · CA · contact PI
IGF::OT::IGF CONTRACT ORIENTATION KICKOFF MEETING PP: 9/22/2015 TO 12/31/2015$4,520
N01 · FY2015 · CA · contact PI
IGF::OT::IGF CONTRACT ORIENTATION AND KICKOFF MEETING 9/30 TO 12/31/2015$1,024
N01 · FY2015 · CA · contact PI
Preclinical Toxicology and Pharmacology of Drugs for Cancer$258,341
N01 · FY2011 · CA · contact PI
Preclinical Toxicology and Pharmacology of Drugs for Cancer$7,000,000
N01 · FY2010 · CA · contact PI
Preclinical Toxicology and Pharmacology of Drugs for Cancer$1,322,758
N01 · FY2010 · CA · contact PI
In Vitro And In Vivo Screening of chemopreventive agents$1,047,642
N01 · FY2010 · CA · contact PI
In Vitro And In Vivo Screening of chemopreventive agents$1,017,128
N01 · FY2009 · CA · contact PI